Literature DB >> 29623837

New Light on An Old Friend: Targeting PUMA in Radioprotection and Therapy of Cardiovascular and Neurodegenerative Diseases.

Ales Tichy1,2, Jan Marek2, Radim Havelek3, Jaroslav Pejchal4, Martina Seifrtova3, Lenka Zarybnicka1, Alzbeta Filipova1, Martina Rezacova3, Zuzana Sinkorova1.   

Abstract

This review summarizes recent progress in understanding the role of p53-upregulated mediator of apoptosis (PUMA) in molecular pathways with respect to its potential therapeutic applications. Particular emphasis is given to the PUMA´s role in ionizing radiation-induced signalling as radiotoxicity of normal tissue is mediated mostly via apoptosis. PUMA and its p53-dependent and p53- independent induction are described and potential use as a new target for the development of radioprotective agents is suggested. Further implications, including targeting PUMA to prevent and treat cardiovascular and neurodegenerative diseases, are also discussed together with an overview of other therapeutic applications. Finally, basic chemical structures for the development of novel PUMA modulators such as pifithrine derivatives, kinase inhibitors or modulators of Bcl-2 protein family are described. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  PUMA; brain; hearth; ionizing radiation; radioprotection; small molecule inhibitor.

Mesh:

Substances:

Year:  2018        PMID: 29623837     DOI: 10.2174/1389450119666180406110743

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  2 in total

Review 1.  The role of P53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseases.

Authors:  Mei Li
Journal:  Apoptosis       Date:  2021-03-30       Impact factor: 4.677

2.  Hirsutanol A inhibits T-acute lymphocytic leukemia Jurkat cell viability through cell cycle arrest and p53-dependent induction of apoptosis.

Authors:  Fangfang Zhong; You Yang; Danwei Ren; Sili Long; Xiang Qin; Jing Liu; Yan Zeng; Wenjian Lan; Wenzhe Ma; Wenjun Liu
Journal:  Exp Ther Med       Date:  2021-05-11       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.